Condition

Non-small Cell Lung Cancer (NSCLC) clinical trials and research

• 62Clinical trials
• 2New in 30 days
• 48Countries

Newest Non-small Cell Lung Cancer (NSCLC) clinical trials

All recruiting trials (62)

• CR-002 study in adults with advanced solid tumors

  This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors

  Recruiting at 3 sites Phase 1/2 Crescent Biopharma, Inc. · Austin, Texas and 2 other locations · NCT07909031

• NSCLC biomarker study using tumor and blood samples to link genetics with prognosis and immunotherapy response

  Researchers will test tumor tissue and blood from about 300 NSCLC patients to find genomic and immune markers that predict prognosis and response to immunotherapy.

  Recruiting at 20 sites Hellenic Cooperative Oncology Group · Limassol and 19 other locations · NCT07900581

• Wireless home prehabilitation for older adults with NSCLC awaiting lung surgery

  This study tests whether a personalized home exercise program guided by wearable devices can improve lung function for older NSCLC patients preparing for curative lung surgery.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07809763

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• Targeted radioligand therapy for several solid tumors using DWJ155 imaging and treatment

  A phase 1 study tests [177Lu]Lu-DWJ155 for treatment and [68Ga]Ga-DWJ155 for imaging in adults with certain breast cancers, NSCLC, GEJ cancer, or bladder cancer who have not benefited from standard therapies.

  Recruiting at 6 sites Phase 1 Novartis · Omaha, Nebraska and 5 other locations · NCT07660055

• First-in-human imaging study of 68Ga-DFC413 and comparison with 68Ga-NNS309 in solid tumors

  This study tests a new radioactive imaging agent, 68Ga-DFC413, to see how it behaves in patients with several solid tumors and compares it to 68Ga-NNS309.

  Recruiting at 2 sites Phase 1 Novartis · Odense C and 1 other locations · NCT07630961

• INV-8989 in KRAS G12D-mutant advanced solid tumors

  This study tests INV-8989 to see if it can be safely given and potentially help patients with KRAS G12D-mutant advanced solid tumors.

  Recruiting Phase 1/2 Shenzhen Ionova Life Sciences Co., Ltd. · Guangzhou, Guangdong · NCT07610798

• KRAS G12D NSCLC: setidegrasib plus docetaxel against docetaxel alone

  This study tests whether adding setidegrasib to docetaxel helps people with KRAS G12D–mutant non-small cell lung cancer who have already progressed after platinum-based therapy.

  Recruiting at 30 sites Phase 3 Astellas Pharma Inc · Glendale, California and 29 other locations · NCT07566052

• Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer

  This study will try giving amivantamab together with platinum chemotherapy to adults with metastatic NSCLC who have specific EGFR mutations to see how long their cancer stays controlled and how safe the treatment is.

  Recruiting at 11 sites Groupe Francais De Pneumo-Cancerologie · Aix-en-Provence and 15 other locations · NCT07563205

• Dose-finding of EXS74539 (REC-4539) in select solid tumors

  This study will try different doses of the experimental drug EXS74539 in adults with select solid tumors to find a safe and tolerable dose.

  Recruiting at 3 sites Phase 1 Exscientia AI Limited · Los Angeles, California and 2 other locations · NCT07517198

• Tislelizumab treatment for people with lung cancer in routine care

  We will see how tislelizumab is used and how patients with resectable, locally advanced, or extensive-stage lung cancer do when treated in everyday clinical care in Germany and Austria.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sankt Pölten, Lower Austria and 1 other locations · NCT07510724

• BPI-572270 in RAS-mutant advanced solid tumors (including NSCLC, CRC, PDAC)

  This study tests whether BPI-572270 is safe and tolerable in adults with RAS-mutant advanced solid tumors and looks for signs of clinical activity.

  Recruiting Phase 1/2 Betta Pharmaceuticals Co., Ltd. · Blacktown, New South Wales and 6 other locations · NCT07435038

• Biomarker-guided donor CAR-NK therapy targeting one or two tumor antigens for advanced solid tumors

  This treatment tries donor-derived CAR-NK cells that target one or two tumor antigens for adults with advanced solid tumors such as breast, NSCLC, colorectal, and recurrent prostate cancer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410494

• Combining RAS(ON) inhibitors with ivonescimab for adults with RAS‑mutant advanced solid tumors

  This trial will test whether combining RAS(ON) inhibitors with ivonescimab is safe and can shrink or control tumors in adults with advanced or metastatic solid tumors that have RAS mutations.

  Recruiting at 19 sites Phase 1/2 Revolution Medicines, Inc. · Scottsdale, Arizona and 18 other locations · NCT07397338

• Pumitamig vs pembrolizumab for first-line advanced NSCLC with PD‑L1 ≥50% (ROSETTA Lung-202)

  This will test if pumitamig works better than pembrolizumab as the first treatment for people with advanced non-small cell lung cancer and PD‑L1 levels of 50% or higher.

  Recruiting at 180 sites Phase 3 Bristol-Myers Squibb · Daphne, Alabama and 282 other locations · NCT07361510

• Pumitamig versus durvalumab after chemoradiation for unresectable stage III NSCLC

  This trial tests whether Pumitamig or durvalumab works better to keep unresectable stage III non-small cell lung cancer from coming back after concurrent chemoradiation.

  Recruiting at 201 sites Phase 3 Bristol-Myers Squibb · Daphne, Alabama and 258 other locations · NCT07361497

• RMC-5127 for advanced cancers with KRAS G12V mutation

  This trial will test whether the experimental drug RMC-5127, alone or with daraxonrasib or cetuximab, helps adults with advanced KRAS G12V-mutant solid tumors.

  Recruiting at 9 sites Phase 1 Revolution Medicines, Inc. · New Haven, Connecticut and 8 other locations · NCT07349537

• Integrated wearable-based perioperative care for NSCLC patients undergoing thoracic surgery

  This study tests whether a wearable-enabled digital perioperative rehab program improves recovery for adults with NSCLC having thoracic surgery compared with standard care.

  Recruiting West China Hospital · Chengdu · NCT07310056

• Datopotamab deruxtecan versus docetaxel for previously treated TROP2-positive advanced non-squamous NSCLC

  This trial tests whether datopotamab deruxtecan works better than docetaxel for people with TROP2-positive advanced or metastatic non-squamous NSCLC who have already received prior therapy and do not have actionable genomic alterations.

  Recruiting at 182 sites Phase 3 AstraZeneca · Chandler, Arizona and 205 other locations · NCT07291037

• Rina-S treatment for advanced non-small cell lung cancer

  This Phase 2 trial will test whether Rina-S by itself can shrink or control advanced non-small cell lung cancer in people whose cancer has progressed after prior treatment.

  Recruiting at 102 sites Phase 2 Genmab · Fountain Valley, California and 101 other locations · NCT07288177

• IDE892 alone and with IDE397 for MTAP-deleted advanced solid tumors

  This trial tests IDE892 by itself and combined with IDE397 in adults whose advanced solid tumors have MTAP deletion and have progressed after standard treatments.

  Recruiting at 23 sites Phase 1 IDEAYA Biosciences · Goodyear, Arizona and 22 other locations · NCT07277413

• STRO-004 treatment in adults with recurrent or metastatic solid tumors

  This study will test whether STRO-004, alone and with pembrolizumab, is safe and can shrink tumors in adults with several types of metastatic cancers that often express Tissue Factor.

  Recruiting at 9 sites Phase 1 Sutro Biopharma, Inc. · San Diego, California and 8 other locations · NCT07227168

• BMS-986523 alone and with other cancer medicines for advanced KRAS-altered solid tumors

  This treatment tests whether BMS-986523, alone or combined with chemotherapy or immunotherapy, helps people with advanced KRAS-altered lung, colorectal, or pancreatic cancers.

  Recruiting at 6 sites Phase 1/2 Bristol-Myers Squibb · Baltimore, Maryland and 7 other locations · NCT07223047

• WSD0922-FU plus osimertinib for EGFR-mutant advanced NSCLC with C797S or new brain metastases

  This trial will test whether adding WSD0922-FU to osimertinib helps adults with advanced EGFR-mutant NSCLC who have the C797S resistance mutation or newly diagnosed brain metastases.

  Recruiting at 3 sites Phase 1/2 Wayshine Biopharm, Inc. · Fuzhou, Fujian and 2 other locations · NCT07206498

• DNA and RNA testing from bronchial lavage to guide genetic analysis in advanced NSCLC

  The team will test whether analyzing DNA and RNA from bronchial lavage (wash) samples gives useful next-generation sequencing (NGS) results for people with advanced non-small cell lung cancer who need genetic testing.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna · NCT07188480

• GI-108 monotherapy for people with advanced or metastatic solid tumors

  We are testing GI-108 by itself to see if it is safe and can shrink tumors in people with advanced or metastatic solid tumors, including lung, head and neck, and pancreatic cancers.

  Recruiting at 3 sites Phase 1/2 GI Innovation, Inc. · Seoul and 2 other locations · NCT07172802

• Nivolumab with chemotherapy as neoadjuvant therapy for resectable NSCLC in Taiwan

  This real-world study tests whether adding nivolumab to chemotherapy before surgery helps people with NSCLC in Taiwan.

  Recruiting at 9 sites Ono Pharmaceutical Co., Ltd. · Kaohsiung City and 8 other locations · NCT07169708

• Taletrectinib versus placebo as adjuvant therapy for ROS1-positive early-stage non-small cell lung cancer

  This study will test whether taking taletrectinib after surgery can help prevent cancer from coming back in adults whose early-stage NSCLC tumors have a ROS1 fusion.

  Recruiting at 33 sites Phase 3 Nuvation Bio Inc. · Los Angeles, California and 32 other locations · NCT07154706

• TH9619 for advanced solid tumors (Phase 1/2)

  This trial will try different doses of TH9619 in adults with advanced solid tumors (including colorectal, head and neck, non-small cell lung, and gastroesophageal cancers) to find a recommended dose and check safety.

  Recruiting at 4 sites Phase 1/2 OneCarbon · Villejuif and 3 other locations · NCT07151040

• Gilteritinib for adults with advanced ALK-positive non-small cell lung cancer

  This phase 1 trial tests whether gilteritinib can help adults with advanced ALK-positive non-small cell lung cancer who have progressed after prior ALK inhibitor treatment.

  Recruiting at 16 sites Phase 1 Astellas Pharma Inc · Fullerton, California and 16 other locations · NCT07140016

• Vebreltinib plus furmonertinib for EGFR‑TKI–resistant NSCLC with c‑MET amplification

  This study tests whether giving vebreltinib together with furmonertinib can help people with advanced NSCLC that developed c‑MET amplification after their EGFR‑targeted therapy stopped working.

  Recruiting at 2 sites Phase 1/2 Peking University Cancer Hospital & Institute · Neimeng, Neimeng and 11 other locations · NCT07087223

• Personalized immunochemotherapy for lung cancer using ctDNA guidance

  This study is testing if using blood tests to check for cancer DNA can help doctors give better and safer treatment cycles to patients with operable non-small cell lung cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06977074

• Evaluating MT-4561 in Patients with Advanced Solid Tumors

  This study is testing a new drug called MT-4561 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 6 sites Phase 1/2 Tanabe Pharma America, Inc. · Los Angeles, California and 5 other locations · NCT06943521

• Perioperative iparomlimab and tuvonralimab with or without chemotherapy for resectable NSCLC

  This study will test whether giving the immunotherapy regimen QL1706 (iparomlimab and tuvonralimab) before and around the time of surgery, with or without platinum-based chemotherapy, helps people with resectable stage II–IIIB non-small cell lung cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT06897046

• JYP0015 for adults with advanced RAS‑mutant solid tumors

  This trial tests whether the oral drug JYP0015 is safe and can shrink tumors in adults whose advanced solid cancers have specific RAS mutations.

  Recruiting Phase 2 Guangzhou JOYO Pharma Co., Ltd · Beijing, Beijing Municipality · NCT06895031

• Using liquid biopsy from EBUS-TBNA fluid to diagnose lung cancer

  This study is testing if analyzing fluid from a specific lung procedure can help diagnose lung cancer in patients who are suspected to have it but have had negative test results.

  Recruiting Barzilai Medical Center · Ashkelon · NCT06889467

• Evaluating SHR-1826 with other cancer therapies for lung cancer

  This study is testing if a new drug called SHR-1826, when combined with other cancer treatments, can help people with non-small cell lung cancer feel better and respond well to therapy.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shanghai, Shanghai Municipality · NCT06754930

• Using incentive spirometry to help lung cancer patients during treatment

  This study is testing whether using an incentive spirometer can help lung cancer patients breathe better and feel healthier during and after their treatment.

  Recruiting Cooper Norcross Health · Camden, New Jersey · NCT06688422

• Repeat chest radiation followed by durvalumab plus ceralasertib for recurring Stage III NSCLC after PACIFIC

  This trial will test whether giving repeat chest radiotherapy followed two weeks later by the immunotherapy durvalumab together with the drug ceralasertib helps people with Stage III non-small cell lung cancer who have a thoracic relapse after the PACIFIC treatment.

  Recruiting at 4 sites Phase 2 Mario Negri Institute for Pharmacological Research · Brescia and 8 other locations · NCT06680050

• Analyzing the effects of low-dose nivolumab with chemotherapy for lung cancer treatment

  This study is testing if a low dose of nivolumab combined with chemotherapy can help people with early-stage non-small cell lung cancer respond better to treatment.

  Recruiting Phase 2 Fundação Faculdade Regional de Medicina de São José do Rio Preto · São José do Rio Preto, São Paulo · NCT06667154

• Testing a new drug for advanced lung cancer resistant to previous treatments

  This study is testing a new drug for people with advanced lung cancer that hasn’t responded to previous treatments to see if it can help them.

  Recruiting at 18 sites Phase 1/2 Pierre Fabre Medicament · Nashville, Tennessee and 17 other locations · NCT06567015

• Evaluating a new treatment for advanced malignant tumors

  This study is testing a new drug called BMS-986463 to see if it is safe and effective for people with advanced cancers like ovarian and lung cancer.

  Recruiting at 7 sites Phase 1 Bristol-Myers Squibb · Los Angeles, California and 16 other locations · NCT06476808

• Cell therapy for patients with advanced solid tumors

  This study is testing a new cell therapy using patients' own immune cells to see if it can help people with advanced solid tumors who haven't responded to other treatments.

  Recruiting Beijing Geekgene Technology Co., LTD · Zhengzhou, Henan · NCT06431100

• Investigating HER3-DXd for advanced solid tumors

  This study is testing a new drug called HER3-DXd to see if it can safely help people with advanced solid tumors like melanoma, head and neck cancer, and gastric cancer who have already tried other treatments.

  Recruiting at 92 sites Phase 2 Daiichi Sankyo · Duarte, California and 95 other locations · NCT06172478

• Combining sacituzumab tirumotecan with pembrolizumab for advanced lung cancer

  This study is testing if combining two cancer treatments, sacituzumab tirumotecan and pembrolizumab, can help people with advanced lung cancer live longer compared to just using pembrolizumab alone.

  Recruiting at 154 sites Phase 3 Merck Sharp & Dohme LLC · Phoenix, Arizona and 219 other locations · NCT06170788

• Evaluating RAS inhibitors for advanced lung cancer

  This study is testing new RAS inhibitors combined with standard treatments to see if they can help people with advanced lung cancer that has specific RAS mutations.

  Recruiting at 53 sites Phase 1/2 Revolution Medicines, Inc. · Gilbert, Arizona and 97 other locations · NCT06162221

• Evaluating RMC-6291 and RMC-6236 for Advanced KRAS G12C Mutant Solid Tumors

  This study is testing a new combination of drugs to see if they can safely help adults with advanced solid tumors that have a specific KRAS mutation.

  Recruiting at 52 sites Phase 1/2 Revolution Medicines, Inc. · Duarte, California and 55 other locations · NCT06128551

• Comparing systemic therapy alone versus with local treatment for advanced lung cancer

  This study is testing if adding local treatments like surgery or radiation to standard therapy can help people with advanced lung cancer live longer and feel better after their initial treatment.

  Recruiting at 7 sites Swiss Cancer Institute · Aarau and 6 other locations · NCT06114108

• Evaluating RMC-9805 for KRAS G12D-Mutant Solid Tumors

  This study is testing a new drug called RMC-9805 to see if it can safely help adults with solid tumors that have a specific KRAS G12D mutation.

  Recruiting at 17 sites Phase 1 Revolution Medicines, Inc. · Sacramento, California and 16 other locations · NCT06040541

• Testing KO-2806 for advanced solid tumors

  This study is testing a new treatment called KO-2806 for adults with advanced solid tumors that have certain genetic changes to see if it can help them feel better.

  Recruiting at 38 sites Phase 1 Kura Oncology, Inc. · Phoenix, Arizona and 37 other locations · NCT06026410

• Assessing GTAEXS617 for advanced solid tumors

  This study is testing a new treatment called GTAEXS617 to see if it can help people with advanced solid tumors, like certain types of cancer, when other treatments haven't worked.

  Recruiting at 15 sites Phase 1/2 Exscientia AI Limited · Los Angeles, California and 14 other locations · NCT05985655

• Comparing two treatments for advanced lung cancer

  This study is testing whether a new drug called sotorasib with chemotherapy works better than pembrolizumab with chemotherapy for people with advanced lung cancer that has a specific KRAS mutation.

  Recruiting at 312 sites Phase 3 Amgen · Santa Barbara, California and 417 other locations · NCT05920356

• Pembrolizumab treatment for advanced non-small cell lung cancer in patients with poor performance status

  This study is testing if pembrolizumab can improve the quality of life for patients with advanced non-small cell lung cancer who can't receive standard treatments because they are not feeling well enough.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT05589818

• Investigating AP203 for advanced solid tumors

  This study is testing a new treatment called AP203 to see if it can help adults with advanced solid tumors, like lung cancer and head and neck cancer, feel better and fight their disease.

  Recruiting Phase 1/2 AP Biosciences Inc. · Taipei · NCT05473156

• Evaluating RMC-6236 for advanced solid tumors with specific RAS mutations

  This study is testing a new drug called RMC-6236 to see if it can help adults with advanced solid tumors that have certain RAS mutations.

  Recruiting at 21 sites Phase 1/2 Revolution Medicines, Inc. · Orange, California and 20 other locations · NCT05379985

• Combining Dacomitinib and Anlotinib for Advanced Lung Cancer Treatment

  This study is testing if combining two drugs, dacomitinib and anlotinib, can help people with advanced lung cancer that has a specific mutation feel better and improve their treatment results.

  Recruiting Phase 1/2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT05271916

• Zanzalintinib with immune checkpoint drugs for advanced solid tumors

  This trial will test whether zanzalintinib alone or combined with immune drugs (nivolumab, with or without ipilimumab or relatlimab) is safe and helps people with advanced or metastatic solid tumors such as renal cell, prostate, urothelial, and liver cancers.

  Recruiting at 101 sites Phase 1 Exelixis · Phoenix, Arizona and 121 other locations · NCT05176483

• Evaluating NX-1607 for advanced cancers

  This study is testing a new treatment called NX-1607 to see if it can help people with advanced cancers who have run out of other options.

  Recruiting at 15 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 16 other locations · NCT05107674

• Survey of Brigatinib for treating non-small cell lung cancer

  This study looks at how safe Brigatinib is for Japanese patients with non-small cell lung cancer while they take the medication as part of their regular treatment.

  Recruiting Takeda · Tokyo · NCT05100069

• Hippocampal-sparing radiation for lung cancer patients

  This study tests a new type of radiation therapy for lung cancer patients to see if it can prevent brain cancer while protecting their memory.

  Recruiting Phase 2/3 Chang Gung Memorial Hospital · Taoyuan · NCT02448992

• Evaluating EGFR-TKI treatments in lung cancer patients

  This study is testing how well different EGFR-TKI treatments work for people with advanced lung cancer and looking at how genetic factors and drug levels affect their results.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT01994057

• Immune response to a MUC1 peptide vaccine for lung cancer

  This study is testing a new vaccine for lung cancer to see if it can help boost the immune response in people with non-small cell lung cancer.

  Recruiting Phase 1/2 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT01720836

Related topics

Quick answers

How many Non-small Cell Lung Cancer (NSCLC) clinical trials are recruiting right now?

62, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 48 countries. The most sites are in United States (31 trials), China (24 trials), Spain (16 trials), France (16 trials), Italy (14 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 20, Phase 1: 12, Phase 2: 8, Phase 3: 8. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →